摘要:
The invention provides antifungal compounds, antifungal compositions, and intermediates for the preparation of antifungal compounds and antifungal compositions. The invention also provides methods of inhibiting fungi and methods of treating fungal infections, for example, with a compound or composition described herein. The antifungal compositions can include antifungal adjuvants such as essential oils or essential oil extracts, which adjuvants further improve the antifungal activity of the compositions.
摘要:
Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.
摘要:
The present invention relates to tetracyclic indole compounds of formula (I); wherein R 1 , R 2 , R 14 , R 15 , A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
摘要:
The present invention relates to tetracyclic indole compounds of formula (I); wherein R 1 , R 2 , R 14 , R 15 , A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
摘要:
The invention relates to malonamide derivatives of formula (I), wherein: R 1 is one of the following groups (Formulae a), b), c), d)); R 2 is lower alkyl, lower alkinyl, -(CH 2 ) n -O-lower alkyl, -(CH 2 ) n -S-lower alkyl, -(CH 2 ) n -CN, -(CR'R") n -CF 3 , -(CR'R") n -CHF 2 , -(CR'R") n -CH 2 F, -(CH 2 ) n -C(O)O-lower alkyl, -(CH 2 ) n -halogen, or is -(CH 2 ) n -cycloalkyl, optionally substituted by one or more substituents, selected from the group consisting of phenyl, halogen or CF 3 ; R',R" are independently from n and from each other hydrogen, lower alkyl, lower alkoxy, halogen or hydroxy; R 3 , R 4 are independently from each other hydrogen, lower alkyl, lower alkoxy, phenyl or halogen; R 5 is hydrogen, lower alkyl, -(CH 2 ) n -CF 3 or -(CH 2 ) n -cycloalkyl; R 6 is hydrogen or halogen; R 7 is hydrogen or lower alkyl; R 8 is hydrogen, lower alkyl, lower alkinyl, -(CH 2 ) n -CF 3 ,-(CH 2 ) n -cycloalkyl or -(CH 2 ) n -phenyl, optionally substituted by halogen; R 9 is hydrogen, lower alkyl, -C(O)H, -C(O)-lower alkyl, -C(O)-CF 3 ,-C(O)-CH 2 F,-C(O)-CHF 2 ,-C(O)-cycloalkyl,-C(O)-(CH 2 ) n -O-lower alkyl,-C(O)O-(CH 2 ) n -cycloalkyl, -C(O)-phenyl, optionally substituted by one or more substituents selected from the group consisting of halogen or -C(O)O-lower alkyl, or is -S(O) 2 -lower alkyl, -S(O) 2 -CF 3 ,-(CH 2 ) n -cycloalkyl or is -(CH 2 ) n -phenyl, optionally substituted by halogen; n is 0, 1, 2, 3 or 4; and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixture thereof. These compounds may be used for the treatment of Alzheimer’s disease.
摘要:
The present invention relates to novel prodrugs of pharmaceutical compounds containing one or more N-H bonds. More specifically, the present embodiment of the invention relates to prodrugs wherein sulfur-containing promoieties are attached to pharmaceutical compounds which contain one or more N-H bonds to produce prodrugs containing at least one N-S bond. These N-S bond-containing prodrugs could have optimized stability, solubility, cell membrane permeability, pharmacokinetic properties and other pharmaceutical properties over the pharmaceutical compounds from which they are formed, depending upon the nature of the promoiety. Reversion of the prodrug to the parent pharmaceutical compound occurs by the reaction of the prodrugs with thiol molecules such as cysteine, glutathione or any other thiol containing molecule. Further, the present invention relates to methods of making N-S bond-containing prodrugs of pharmaceutical compounds containing one or more N-H bonds whereby sulfur-containing promoieties are attached to the parent compounds to create at least one N-S bond.
摘要:
A compound having a general formula (II) wherein R1 is saturated or unsaturated alkyl, amino-alcohol, diamino, cycloalkyl, and C(=O)(CH2)nNR'R'', (CH2)nCHOHCH2NR'R'', wherein n is an integer; RQ, RT, R', and R'' are each independently a hydrogen, halogen, hydroxyl, saturated, unsaturated, aliphatic, or branched alkyl, substituted or unsubstituted (CH2)m-(hetero)aryl, and sulfonylamide; q and t are each an integer independently selected from 1-4; and pharmaceutically acceptable salts thereof, and the new therapeutic uses thereof and similar compounds as defibrillating, and/or anti-fibrillatory, and/or anti-arrhythmic and/or anti-ischemic drugs.
摘要:
The present invention relates to use of pyrimido-diazepinone compounds that are able to modulate protein kinases such as doublecortin-like kinase (DCLK1) and doublecortin-like kinase 2 (DCLK2), which are members of serine/threonine-protein kinase family and Ca 2+ /calmodulin-dependent protein kinase class of enzymes, and the use of such compounds in the treatment of various diseases, disorders or conditions.
摘要:
The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.